Department of Medical Genetics, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, No. 1, Keyuan Road 4, Gaopeng Street, Chengdu, Sichuan 610041, China.
Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Hum Reprod. 2017 Jul 1;32(7):1521-1531. doi: 10.1093/humrep/dex100.
What is the influence of copy number variation (CNV) in functional RNA binding motif protein Y-linked family 1 (RBMY1) on spermatogenic phenotypes?
The RBMY1 functional copy dosage is positively correlated with sperm motility, and dosage insufficiency is an independent risk factor for asthenozoospermia.
RBMY1, a multi-copy gene expressed exclusively in the adult testis, is one of the most important candidates for male infertility in the azoospermia factor (AZF) region of the Y-chromosome. RBMY1 encodes an RNA-binding protein that serves as a pre-mRNA splicing regulator during spermatogenesis, and male mice deficient in Rbmy are sterile.
STUDY DESIGN, SIZE, DURATION: A total of 3127 adult males were recruited from 2009 to 2016; of this group, the dosage of RBMY1 functional copy were investigated in 486 fertile males. In the remaining 2641 males with known spermatogenesis status, 1070 Y-chromosome haplogroup (Y-hg) O3* or O3e carriers without chromosomal aberration or known AZF structure mutations responsible for spermatogenic impairment, including 506 men with normozoospermia and 564 men with oligozoospermia or/and asthenozoospermia, were screened, and the RBMY1 functional copy dosage and copy conversion were determined to explore their associations with sperm phenotypes. The correlation between RBMY1 dosage and its mRNA level or RBMY1 protein level and the correlation between sperm RBMY1 level and motility were analysed in 15 testis tissue samples and eight semen samples. Ten additional semen samples were used to confirm the subcellular localization of RBMY1 in individual sperm.
PARTICIPANTS/MATERIALS, SETTING, METHODS: All the Han volunteers donating whole blood, semen and testis tissue were from southwest China. RBMY1 copy number, copy conversion, mRNA/protein amount and protein location in sperm were detected using the AccuCopy® assay method, paralog ratio test, quantitative PCR, western blotting and immunofluorescence staining methods, respectively.
This study identified Y-hg-independent CNV of functional RBMY1 in the enrolled population. A difference in the distribution of RBMY1 copy number was observed between the group with normal sperm motility and the group with asthenozoospermia. A positive correlation between the RBMY1 copy dosage and sperm motility was identified, and the males with fewer than six copies of RBMY1 showed an elevated risk for asthenozoospermia relative to those with six RBMY1 copies, the most common dosage in the population. The RBMY1 copy dosage was positively correlated with its mRNA and protein level in the testis. Sperm with high motility were found to carry more RBMY1 protein than those with relatively low motility. The RBMY1 protein was confirmed to predominantly localize in the neck and mid-piece region of sperm as well as the principal piece of the sperm tail. Our population study completes a chain of evidence suggesting that RBMY1 influences the susceptibility of males to asthenozoospermia by modulating sperm motility.
High sequence similarity between the RBMY1 functional copies and a large number of pseudogenes potentially reduces the accuracy of the copy number detection. The mechanism underlying the CNV in RBMY1 is still unclear, and the effect of the structural variations in the RBMY1 copy cluster on the copy dosage of other protein-coding genes located in the region cannot be excluded, which may potentially bias our observations.
Asthenozoospermia is a multi-factor complex disease with a limited number of proven susceptibility genes. This study identified a novel genomic candidate independently contributing to the condition, enriching our understanding of the role of AZF-linked genes in male reproduction. Our finding provides insight into the physiological and pathological characteristics of RBMY1 in terms of sperm motility, supplies persuasive evidence of the significance of RBMY1 copy number analysis in the clinical counselling of male infertility resulting from asthenozoospermia.
STUDY FUNDING/COMPETING INTEREST(S): This work was funded by the National Natural Science Foundation of China (Nos. 81370748 and 30971598). The authors have no conflicts of interest.
功能 RNA 结合基序蛋白 Y 连锁家族 1(RBMY1)的拷贝数变异(CNV)对精子发生表型有何影响?
RBMY1 功能拷贝的剂量与精子活力呈正相关,剂量不足是弱精子症的独立危险因素。
RBMY1 是一个多拷贝基因,仅在成年睾丸中表达,是 Y 染色体无精子因子(AZF)区域中男性不育最重要的候选基因之一。RBMY1 编码一种 RNA 结合蛋白,在精子发生过程中作为前体 mRNA 剪接调节剂,缺乏 Rbmy 的雄性小鼠是不育的。
研究设计、规模、持续时间:2009 年至 2016 年期间共招募了 3127 名成年男性;其中,486 名生育能力正常的男性调查了 RBMY1 功能拷贝的剂量。在已知生精状态的 2641 名男性中,筛选了 1070 名 Y 染色体单倍型(Y-hg)O3*或 O3e 无染色体异常或已知导致生精障碍的 AZF 结构突变的携带者,包括 506 名正常精子症患者和 564 名少精子症或/和弱精子症患者,并确定了 RBMY1 功能拷贝的剂量和拷贝转换,以探讨它们与精子表型的关系。分析了 15 个睾丸组织样本和 8 个精液样本中 RBMY1 剂量与其 mRNA 水平或 RBMY1 蛋白水平之间的相关性,以及精子中 RBMY1 水平与活力之间的相关性。另外 10 个精液样本用于确认 RBMY1 在单个精子中的亚细胞定位。
参与者/材料、设置、方法:所有来自中国西南部的自愿捐献血液、精液和睾丸组织的汉族志愿者。使用 AccuCopy®检测方法、等位基因比值检测、定量 PCR、western blot 和免疫荧光染色方法分别检测 RBMY1 拷贝数、拷贝转换、mRNA/蛋白量和精子中 RBMY1 蛋白的位置。
本研究在入组人群中发现了与 Y-hg 无关的功能性 RBMY1 的 CNV。在具有正常精子活力的组和具有弱精子症的组之间观察到 RBMY1 拷贝数的分布存在差异。确定了 RBMY1 拷贝剂量与精子活力之间存在正相关,与携带 6 个 RBMY1 拷贝的人群相比,携带少于 6 个 RBMY1 拷贝的男性患弱精子症的风险增加,这是人群中最常见的剂量。RBMY1 拷贝剂量与睾丸中的 mRNA 和蛋白水平呈正相关。具有高活力的精子被发现携带比相对低活力的精子更多的 RBMY1 蛋白。RBMY1 蛋白主要定位于精子的颈部和中段区域以及精子尾部的主段。我们的人群研究完成了一系列证据链,表明 RBMY1 通过调节精子活力影响男性患弱精子症的易感性。
局限性/谨慎原因:RBMY1 功能拷贝之间的高序列相似性和大量假基因可能降低拷贝数检测的准确性。RBMY1 拷贝数变异的机制仍不清楚,位于该区域的其他蛋白质编码基因的结构变异对其他蛋白质编码基因的拷贝剂量的影响尚不能排除,这可能会影响我们的观察结果。
弱精子症是一种多因素复杂疾病,已证实的易感基因数量有限。本研究确定了一个新的基因组候选基因,独立地参与了该疾病,丰富了我们对 AZF 相关基因在男性生殖中的作用的理解。我们的发现为精子活力方面的 RBMY1 生理和病理特征提供了新的认识,为弱精子症导致的男性不育的 RBMY1 拷贝数分析在临床咨询中的意义提供了有说服力的证据。
研究基金/利益冲突:本工作得到了国家自然科学基金(Nos. 81370748 和 30971598)的资助。作者没有利益冲突。